Abstract Background Cyclosporine A (CsA)-induced cardiac interstitial fibrosis and cardiac
hypertrophy are highly known phenomena; however, the basic mechanisms of CsA …

Purpose Cyclosporine A (CsA)-induced cardiac interstitial brosis and cardiac hypertrophy is
a highly known phenomenon, whereas the basic mechanisms of CsA cardiotoxicity are not …

Background and purpose: The present study investigated the role of the prostaglandin I
2/peroxisome proliferator activator receptor (PGI2/PPAR) signaling pathway in cardiac cell …

Background Regulatory molecule microRNAs (miRNAs) have been implicated in myocardial
fibrosis. However, the specific mechanism by which they lead to myocardial fibrosis remains …

Background Postinfarction cardiac remodeling presents a compensatory mechanism aimed
at mitigating congestive heart failure. It is distinguished by progressive dilatation and …

Cyclosporin A (CsA) is an effective immunosuppressive agent, but its myocardial toxicity
limits its widespread and long-term clinical application. In this study, CsA treatment led to …

Objective Cytochrome P450 2E1 (CYP2E1) is an effective generator of reactive oxygen
species, and it is known to be regulated in the course of progression of myocardial ischemia …

Cardiac fibrosis is a deleterious effect of many cardiovascular diseases. Previous studies
have shown that curcumin has exhibited protective effects on cardiovascular diseases. The …

Celecoxib, a cyclooxygenase-2 (COX-2)-selective nonsteroidal anti-inflammatory drug, has
been shown to inhibit Akt and prevent cardiac remodeling in aortic banding-induced failing …

Myocardial fibrosis (MF) can cause heart remodeling and it is an independent risk factor for
malignant arrhythmias, sudden cardiac death, and other malignant cardiovascular events. It …